MED Medifast Inc

Price (delayed)

$48.93

Market cap

$533.12M

P/E Ratio

5.36

Dividend/share

$6.59

EPS

$9.13

Enterprise value

$460.69M

Medifast is the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, which offers scientifically developed products, clinically proven plans and the support of Coaches and a ...

Highlights
The company's quick ratio has surged by 163% YoY and by 14% QoQ
The price to earnings (P/E) is 64% less than the 5-year quarterly average of 14.8 and 28% less than the last 4 quarters average of 7.4
MED's revenue is down by 33% year-on-year and by 12% since the previous quarter
Medifast's gross profit has decreased by 32% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of MED
Market
Shares outstanding
10.9M
Market cap
$533.12M
Enterprise value
$460.69M
Valuations
Price to book (P/B)
2.65
Price to sales (P/S)
0.5
EV/EBIT
3.65
EV/EBITDA
3.2
EV/Sales
0.43
Earnings
Revenue
$1.07B
EBIT
$126.31M
EBITDA
$144.02M
Free cash flow
$141.17M
Per share
EPS
$9.13
Free cash flow per share
$12.97
Book value per share
$18.5
Revenue per share
$98.5
TBVPS
$28.47
Balance sheet
Total assets
$309.91M
Total liabilities
$108.43M
Debt
$22.01M
Equity
$201.48M
Working capital
$131.73M
Liquidity
Debt to equity
0.11
Current ratio
2.43
Quick ratio
1.63
Net debt/EBITDA
-0.5
Margins
EBITDA margin
13.4%
Gross margin
72.4%
Net margin
9.3%
Operating margin
11.8%
Efficiency
Return on assets
31.3%
Return on equity
53%
Return on invested capital
116.1%
Return on capital employed
58%
Return on sales
11.8%
Dividend
Dividend yield
13.47%
DPS
$6.59
Payout ratio
72.2%

MED stock price

How has the Medifast stock price performed over time
Intraday
-2.12%
1 week
-7.47%
1 month
-8.16%
1 year
-57.57%
YTD
-27.21%
QTD
-27.21%

Financial performance

How have Medifast's revenue and profit performed over time
Revenue
$1.07B
Gross profit
$775.85M
Operating income
$126.4M
Net income
$99.42M
Gross margin
72.4%
Net margin
9.3%
MED's revenue is down by 33% year-on-year and by 12% since the previous quarter
Medifast's gross profit has decreased by 32% YoY and by 11% from the previous quarter
The operating income fell by 32% YoY and by 16% QoQ
MED's net income is down by 31% YoY and by 17% QoQ

Growth

What is Medifast's growth rate over time

Valuation

What is Medifast stock price valuation
P/E
5.36
P/B
2.65
P/S
0.5
EV/EBIT
3.65
EV/EBITDA
3.2
EV/Sales
0.43
The price to earnings (P/E) is 64% less than the 5-year quarterly average of 14.8 and 28% less than the last 4 quarters average of 7.4
The EPS has declined by 29% year-on-year and by 17% since the previous quarter
MED's P/B is 75% below its 5-year quarterly average of 10.6 and 47% below its last 4 quarters average of 5.0
The equity has grown by 30% YoY and by 4.4% from the previous quarter
The P/S is 69% lower than the 5-year quarterly average of 1.6 and 29% lower than the last 4 quarters average of 0.7
MED's revenue is down by 33% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Medifast business performance
MED's ROE is down by 40% YoY and by 22% QoQ
The ROA has decreased by 23% YoY and by 17% from the previous quarter
The return on invested capital has declined by 22% since the previous quarter and by 14% year-on-year
The return on sales has declined by 4.1% since the previous quarter

Dividends

What is MED's dividend history
DPS
$6.59
Dividend yield
13.47%
Payout ratio
72.2%
Recent dividends

Financial health

How did Medifast financials performed over time
The total assets is 186% greater than the total liabilities
The company's quick ratio has surged by 163% YoY and by 14% QoQ
MED's current ratio has soared by 54% year-on-year and by 19% since the previous quarter
Medifast's debt is 89% less than its equity
Medifast's debt to equity has decreased by 35% YoY and by 8% from the previous quarter
The equity has grown by 30% YoY and by 4.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.